Stryker Corporation $SYK Shares Sold by Suncoast Equity Management

Suncoast Equity Management reduced its position in Stryker Corporation (NYSE:SYK) by 8.8% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 105,926 shares of the medical technology company’s stock after selling 10,261 shares during the period. Stryker accounts for approximately 4.2% of Suncoast Equity Management’s holdings, making the stock its 11th biggest holding. Suncoast Equity Management’s holdings in Stryker were worth $33,350,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SYK. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new stake in shares of Stryker during the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter worth $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker during the fourth quarter worth $27,000. Finally, DJE Kapital AG acquired a new position in Stryker in the fourth quarter worth $28,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $338.80 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a fifty day moving average price of $324.61 and a 200 day moving average price of $333.57. The company has a market cap of $129.95 billion, a P/E ratio of 35.11, a PEG ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the business posted $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SYK. Argus set a $370.00 target price on shares of Stryker in a report on Thursday, July 9th. Barclays decreased their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th. Finally, Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.